Fidelity Management and Research, an American multinational financial services company, led a $110m Series D funding round of Poseida Therapeutics, a clinical-stage biotechnology company. Adage Capital Management and Schonfeld Strategic Advisors, as well as a number of unnamed existing investors, participated in the round. “This financing supports the approach we are taking to leverage our broad proprietary gene engineering platform technologies, including the piggyBac DNA Modification System and Cas-CLOVER site-specific gene editing system, for the creation of numerous differentiated cell and gene therapy product candidates,” Eric Ostertag, Poseida’s CEO.